Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.62 |
| ▸ | MEN1 | O00255 | 6/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.62 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16398902 | 0.80 | ALDH1A1 (0.54) | ALDH1A1MEN1KMT2AKDM4ETDP1 | |
| SCHEMBL2992756 | 0.79 | EGFR (0.56) | ALDH1A1MEN1KMT2AKDM4ETDP1 | |
| SCHEMBL27621377 | 0.78 | ALDH1A1 (0.51) | ALDH1A1MEN1KMT2AKDM4ETDP1 | |
| SCHEMBL4167767 | 0.77 | ALDH1A1 (0.54) | ALDH1A1MEN1KMT2AKDM4ETDP1 | |
| SCHEMBL6537368 | 0.77 | ALDH1A1 (0.67) | ALDH1A1MEN1KMT2AKDM4ETDP1 | |
| SCHEMBL317836 | 0.77 | KMT2A (1.00) | ALDH1A1MEN1KMT2AKDM4ETDP1 | |
| SCHEMBL2055470 | 0.76 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2AKDM4ETDP1 | |
| SCHEMBL2379102 | 0.75 | TDP1 (0.62) | ALDH1A1MEN1KMT2AKDM4ETDP1 | |
| SCHEMBL6537643 | 0.74 | MEN1 (0.59) | ALDH1A1MEN1KMT2AKDM4ETDP1 | |
| SCHEMBL6537483 | 0.74 | ALDH1A1 (0.59) | ALDH1A1MEN1KMT2AKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404270-B2 | Quinazoline derivatives as LPA receptor 2 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-09-02 | — | — | US | disclosed |
| EP-4072670-B1 | QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | CHIESI FARM SPA (IT) | 2023-11-22 | — | — | EP | disclosed |
| US-20230063121-A1 | QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-03-02 | — | — | US | disclosed |
| EP-4072670-A1 | QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2022-10-19 | — | — | EP | disclosed |
| CN-114786771-A | Quinazoline derivatives as inhibitors of LPA receptor 2 | 奇斯药制品公司 | 2022-07-22 | — | — | CN | disclosed |
| US-20220056052-A1 | QUINAZOLINE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC | 2022-02-24 | — | — | US | disclosed |
| EP-3902787-A1 | QUINAZOLINE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | Riboscience LLC (US) | 2021-11-03 | — | — | EP | disclosed |
| WO-2021116260-A1 | QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-06-17 | — | — | WO | disclosed |
| WO-2020140001-A1 | QUINAZOLINE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC (US) | 2020-07-02 | — | — | WO | disclosed |
| CN-103492028-B | Sulfonaminoquinoline hepcidin antagonists | 维福（国际）股份公司 | 2017-02-08 | — | — | CN | disclosed |
| WO-2012110603-A1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | WO | disclosed |
| US-8163911-B2 | Arylsulfonylaminomethylphosphonic acid derivatives, the preparation thereof and the use thereof as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-24 | — | — | US | disclosed |
| US-20100261677-A1 | ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| EP-2200987-A1 | ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | Boehringer Ingelheim International GmbH (DE) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009030715-A1 | ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-12 | — | — | WO | disclosed |
| EP-0876345-B1 | HETEROCYCLIC COMPOUNDS AS H+-ATPASES | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-08-18 | — | — | EP | disclosed |
| WO-2004024710-A1 | UREA COMPOUNDS ACTIVE AS VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | WO | disclosed |
| US-6008230-A | TREATING BONE DISEASES CAUSED BY ABNORMAL BONE METABOLISM IN HUMAN BEING OR ANIMALS AS THE INHIBITORS OF BONE RESORPTION OR THE INHIBITORS OF BONE METASTASIS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-12-28 | — | — | US | disclosed |
| EP-0876345-A1 | HETEROCYCLIC COMPOUNDS AS H+-ATPASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-11-11 | — | — | EP | disclosed |
| WO-1997014681-A1 | HETEROCYCLIC COMPOUNDS AS H+-ATPASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404270-B2 | Quinazoline derivatives as LPA receptor 2 inhibitors | LPAR2, LPAR1, LPAR5 | ALDH1A1 2204/4885MEN1 3828/4885KMT2A 1701/4885 |
| US-20100261677-A1 | ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | ARSA, SULT2A1, PMM2 | ALDH1A1 468/4885MEN1 2590/4885KMT2A 494/4885 |
| US-20230063121-A1 | QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | LPAR2, LPAR1, LPAR5 | ALDH1A1 2204/4885MEN1 3828/4885KMT2A 1701/4885 |
| US-20220056052-A1 | QUINAZOLINE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | ENPP1, ENPP3, PDE7A | ALDH1A1 2200/4885MEN1 1734/4885KMT2A 3867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.